Skip to main content

Hypertriglyceridemia triggered acute pancreatitis in pregnancy – diagnostic approach, management and follow-up care


Acute pancreatitis is a pregnancy complication potentially lethal for both the mother and fetus, occurring most frequently in the third trimester or early postpartum. Hypertriglyceridemia may be the cause of important disease in pregnant patients. Patients with triglyceride levels exceeding 1000 mg/dL are at increased risk of developing severe pancreatitis. Diagnostic criteria and management protocols are not specific for pancreatitis complicating pregnancy. Other causes of acute abdominal pain must be considered in the differential diagnosis. Decision-making in the obstetric context is challenging and bears potential legal implications. Pre-pregnancy preventive measures and prenatal antilipemic treatment are mandatory in high risk patients.


Acute pancreatitis (AP) is a rare cause of abdominal pain in pregnancy with a cited incidence of 1/1000–10,000 depending on the diagnostic criteria used and provided accurate diagnosis is not always achieved [1,2,3]. The majority of cases occur in the third trimester or early postpartum and carry an increased maternal and fetal morbidity and mortality potential [4]. Maternal death rate due to pancreatitis was reportedly 37% and fetal death rate 60%, in decline recently as a result of more advanced diagnostic and therapeutic possibilities [5,6,7]. Pregnancy associated pancreatitis may occur on the background of gallstone disease, alcohol abuse and hypertriglyceridemia (HTG) [8,9,10]. It appears that HTG aggravates the severity score and prognosis of disease [7, 11, 12].

AP in pregnancy is a challenge for the clinician since it may be complicated by the onset of labor or obstetrical emergencies. Moreover, the rare occurrence of this condition makes the clinician less suspicious of such an etiology of acute abdominal pain in pregnancy which can delay diagnosis and management and jeopardize fetal outcome. This singularizes further HTG-AP since neither its diagnosis, nor patient approach are fully superposable to the general criteria used for pancreatitis, making this pathology a clinical strategy and medical responsibility issue.

There no currently available obstetric guidelines which highlight the role of HTG and regulate the management of disease are still absent on account of the low incidence rates and scarce clinical data. There are no mentions of pregnancy considerations in guidelines addressing AP management in the general population. Therapy relies on the expertise of the clinician which translates into a susceptibility to medical-legal and malpraxis issues.

Lipid metabolism in pregnancy and HTG induced pancreatitis pathogenesis

Normal pregnancy is characterized by adaptive lipid metabolism changes meant to ensure placental needs and glucose and lipid requirements of the growing fetus: increased glucose production, progesterone synthesis and lipogenesis, diminished lipolysis [13, 14]. In women with abnormal lipoprotein metabolism these changes lead to severe HTG and may precipitate pancreatitis [15]. Although serum triglycerides (TG) peak in the third trimester, total serum TG level rarely exceeds 300 mg/dL (3.3 mmol/L), a concentration that is not sufficient to cause AP.

HTG may be primary – in congenital chylomicronemia syndrome related to lipoprotein lipase or apoproteins C-II deficiency [16], or secondary in patients with obesity or metabolic syndrome, unrecognized or uncontrolled diabetes mellitus, alcohol consumers, drug use (tamoxifen, steroids, diuretics, beta-blockers, atypical antipsychotics) or may lack any predisposing factor [17,18,19].

The exact pathogenesis behind HTG-induced AP is not fully understood. TG accumulating around the pancreas are hydrolyzed by pancreatic lipase leading to the accumulation of high levels of free fatty acids [20]. These are believed to be toxic to acinar cells and the capillary endothelium. At the same time, increased chylomicron concentrations, can lead to capillary plugging, ischemia, and acidosis. In this acidic environment, free fatty acids activate trypsinogen and trigger AP [21].

Diagnostic pitfalls in pregnancy

The diagnosis of AP in pregnancy in difficult since symptoms may mimic any other disease presenting with abdominal pain or the onset of labor. Sometimes, AP onset itself may trigger labor due to peritoneal irritation. Acute medical and surgical conditions presenting with acute abdominal pain must be excluded: myocardial infarction, peptic ulcer, appendicitis, cholecystitis, acute mesenteric ischemia, gastro-intestinal or pancreatic cancer, pyelonephritis etc. Furthermore, obstetric complications must be taken into consideration and carefully ruled out – acute fatty liver of pregnancy, preeclampsia, HELLP syndrome, placental abruption, uterine rupture [22]. The setting of abdominal pain in patients with advanced gestation is particular due to the presence of the enlarged uterus with mechanic upward and lateral displacement on maternal organs, as well as to physiologic changes in pain perception [23]. In term patients with locally complicated disease by acute peri-pancreatic fluid collection it is difficult to achieve diagnosis [16, 17].

HTG-AP cases are typically associated with high serum TG levels (≥1000 mg/dL). However, in certain instances, HTG may be concealed as disease trigger since TG levels drop after a few days of fasting. There have been reports of AP in pregnancy in patients with only HTG as identifiable trigger but at lower levels than the above-mentioned threshold. HTG levels susceptible to activate pancreatitis are thus questionnable [1, 21]. This Moreover, AP diagnosis can be overlooked because serum amylase levels may also be within the normal range at admission [24].

Management and therapeutic options

The clinical presentation of HTG-AP does not differ from other etiologies, except from the diagnostic traps derived from the obstetric context. Once the correct diagnosis achieved, management principles of pregnant patients follow current guidelines for the general population but are complicated by the decision regarding the timing and route of delivery. It is mandatory that HTG are returned to the normal range [24]. However, there are restrictions regarding chronic antilipemic use in pregnancy due to the lack of consistent studies conducted on humans. Following delivery patient approach returns to non-pregnant population protocols.

Lipid lowering agents in pregnancy - Antilipemic agents are the first line of treatment in patients with HTG induced AP of non-pregnant patients. However, these drugs have been only scarcely studied in pregnant women and there is limited information regarding fetal effects [25]. Omega-3 fatty acids are safe for pregnancy use as monotherapy to decrease maternal TG levels, have a rapid onset of action but only moderate effects [26, 27]. Nicotinic acid has only been used in case reports of pregnant women during the first trimester of pregnancy without proven fetal adverse effects [28, 29], however treatment later on in pregnancy has not been advocated. Fibrates use is limited during pregnancy because little data is available from well-designed studies and further research is required to support their use in pregnant women [30]. Statins have potentially teratogenic effects and their use in pregnant patients is restricted, even though studies are controversial [30]. Since moderate risk of fetal developmental abnormality cannot be excluded with statin use, they received FDA (Food and Drug Administration) category X designation [31].

Insulin and heparin - Insulin enhances lipoprotein lipase activity and leads to chylomicron degradation thus reducing HTG, while heparin stimulates the releases of lipoprotein lipase which adheres to endothelial cells and decreases serum TG levels [32]. Long-term heparin use will deplete lipoprotein lipase on the surface of endothelial cells having the opposite HTG triggering effect and lead to pancreatitis. Watts et al. describe this in the case report of a pregnant patient. A case report described a pregnant woman who developed HTG-pancreatitis after long-term heparin use [33].

Apheresis – therapeutic plasma exchange serves to decrease TG levels, reduce inflammatory cytokines, and replace deficient lipoprotein lipase or apolipoproteins when plasma is used as the replacement fluid [34]. In HTG-AP, apheresis may be used as established by the American Society of Apheresis Guidelines [35]. There are several small-scale studies and clinical case which evaluated the use of plasma exchange in pregnant patients rendering it effective and safe [36,37,38,39]. Studies comparing the effect of plasmapheresis versus conservative management on morbidity and mortality in cases of HTG-induced pancreatitis found no statistical difference [40].

Obstetric decisions and maternal-fetal outcome

Pregnancy termination

Interruption of pregnancy is decided by a team involving gastroenterologists, surgeons and obstetricians to minimize fetal loss. Counseling and consent of the couple are mandatory. Confirmed stillbirth, the mandatory use of feto-toxic medication for pancreatitis treatment or organ failure are indications of termination of pregnancy, regardless if requires a term/preterm natural delivery or cesarean section [7]. Pregnancy termination can be regarded as a necessary condition to achieve AP cure [39].

When possible, vaginal delivery is preferable to limit the risk of infection and necrosis associated with laparotomy. However, pregnancy should be terminated by caesarean delivery as soon as possible in case of hyperlipidemic pancreatitis because of the significantly increased risk of maternal and fetal mortality. Emergency surgical delivery is indicated in patients with deteriorated condition after 24–48 h of treatment, no improvement of paralytic ileus, stillbirth, fetal malformations, fetal distress and severe pancreatitis. The potential need to perform prophylactic hysterectomy to avoid the latter risk of uterine wound infection from the pancreatic site should be taken into account, especially in multiparous patients [41].

Maternal outcome

Recent data shows that HTG is a risk factor for delayed pancreatic regeneration after AP [42]. Lipid profile must be monitored long term after recovery and the patient must be counseled regarding the risk of recurrent episodes of AP, hyperlipoproteinemia, diabetes melllitus and hyper-viscosity syndrome in later life.

Fetal implications

The fetus from an AP pregnancy is exposed to the risk of threatened preterm labor, prematurity and death [7, 43, 44]. Regarding the follow-up of fetuses from hyperlipidemic patients, results of pathology studies performed on 6-month-old deceased fetuses of mothers with hypercholesterolemia compared to mothers with normal cholesterol levels revealed the presence of fatty streaks at aortic level [45, 46]. The hypothesis of fetal metabolic programming suggests that HTG in pregnancy may bear later life consequences on the product of conception. Early adjustments to specific nutritional conditions influence the future physiology and continue to be expressed even in the absence of the condition that initiated them [47]. Fetuses from hypertriglyceridaemic pregnancies are at risk for impaired lipid homeostasis and atherosclerosis through yet poorly understood mechanisms. Studies performed on animals have shown that permanent changes in either DNA (deoxyribonucleic acid) methylation or chromatin modification, or the activation of genes involved in immune pathways and fatty acid metabolism are possible pathways of epigenetic metabolic programming during embryonic/fetal development [48,49,50].

Pre-conceptional and prenatal counseling in high risk patients

Patients with HTG taking lipid-lowering therapies should discontinue treatment prior to and during pregnancy since data regarding drug safety are conflicting [29, 41, 51]. They should be informed about the possible exacerbating factors and complications of pregnancy. Lifestyle adjustments are essential, such as a low fat and omega-3 fatty acid rich diet, exercise, abstention from alcohol, and control of secondary triggering factors - diabetes mellitus and drugs which may induce AP (β-adrenal blockers, glucocorticoids, cimetidine, estrogen, oral contraceptives). Excessive weight gain during gestation should be avoided. Glycemic control should be achieved preconceptionally in order to help lower lipid levels, especially in diabetic women [52].

During pregnancy, TG levels should be closely monitored in high risk patients. Timely antilipemic treatment with omega-3 fatty acids and nicotinic acid should de ensured to maintain lipid profile parameters within the normal range. There are authors who support the use of apheresis in the treatment of pregnancy HTG as preventive measure for pancreatitis [53].

The main features which differentiate HTG-AP occurring in pregnancy from the disease occurring in non-pregnant patients are summarized in Table 1. Despite its being an unexpected event in pregnancy, this pathology must be warranted for and looked for given its potentially severe maternal and fetal complications. We may speculate that the rising trend of obesity worldwide may have a negative impact on the incidence of this disease, in pregnancy and otherwise.

Table 1 Acute pancreatitis and HTG induced acute pancreatitis features in pregnant versus non-pregnant patients


HTG induced AP is a rare but devastating complication of pregnancy with high mortality potential for both the mother and fetus. Prophylactic measures are essential, namely avoiding excessive weight gain in pregnancy and ensuring lipid and glycemic control prior to and during gestation. Further studies are required to identify safe treatment options during pregnancy. Guidelines are required to establish specific diagnostic criteria or dictate the management in severe cases which mandate challenging obstetric decisions and may trigger medical-legal implications.

Availability of data and materials

The data in the current paper are publicly available since this a review conducted on the basis of the cited literature.



Acute pancreatitis


Deoxyribonucleic acid


Food and Drug Administration






  1. Zhang DL, Huang Y, Yan L, et al. Thirty-eight cases of acute pancreatitis in pregnancy: a 6-year single center retrospective analysis. J Huazhong Univ Sci Technolog Med Sci. 2013;33:361–7.

    Article  CAS  Google Scholar 

  2. Bahiyah A, Thanikasalam KP, Lim HC, Ray JR. Severe acute pancreatitis in pregnancy. Case Rep Obstet Gynecol. 2015;2015:239068.

    Article  Google Scholar 

  3. Vege SS, Whitcomb DC, Grover S. Clinical manifestations and diagnosis of acute pancreatitis: UpToDate; 2018.

  4. Terzhumanov R, Uchikov A, Uchikova E, Milchev H, Dimov R, Stefanov C. Acute pancreatitis and pregnancy— analysis of a 10 year period of time. Akush Ginekol. 2004;43(7):9–12.

    CAS  Google Scholar 

  5. Sun L, Li W, Geng Y, Shen B, Li J. Acute pancreatitis in pregnancy. Acta Obstet Gynecol Scand. 2011;90(6):671–6.

    Article  Google Scholar 

  6. Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecil Reprod Biol. 2011;159:261–6.

    Article  CAS  Google Scholar 

  7. Luo L, Zen H, Xu H, Zhu Y, Liu P, et al. Clinical characteristics of acute pancreatitis in pregnancy: experience based on 121 cases. Arch Gynecol Obstet. 2018;297(2):333–9.

    Article  CAS  PubMed  Google Scholar 

  8. Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90:2134. 8540502.

    CAS  PubMed  Google Scholar 

  9. Zhu Y, Pan X, Zeng H, et al. A study on the etiology, severity, and mortality of 3260 patients with acute pancreatitis according to the revised Atlanta classification in Jiangxi, China over an 8-year period. Pancreas. 2017;46:504.

    Article  CAS  PubMed  Google Scholar 

  10. Cruciat G, Stamatian F, Puscas M, Cruciat C, Ispasoiu F, Muresan D. Acute Pancreatitis in a Pregnant Woman with Acute Fatty Liver Dystrophy. A Case Report. J Gastrointestin Liver Dis. 2007;16(2):193–6.

    PubMed  Google Scholar 

  11. Kayatas SE, Eser M, Cam C, Cogendez E, Guzin K. Acute pancreatitis associated with hypertriglyceridemia: a life-threatening complication. Arch Gynecol Obstet. 2010;281(3):427–9.

    Article  PubMed  Google Scholar 

  12. Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110:1497–503.

    Article  CAS  PubMed  Google Scholar 

  13. Vrijkotte TG, Krukziener N, Hutten BA, et al. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. J Clin Endocrinol Metab. 2012;97(11):3917–25.

    Article  CAS  PubMed  Google Scholar 

  14. Rauschert S, Gázquez A, Uhl O, Kirchberg FF, Demmelmair H, Ruíz-Palacios M, Prieto-Sánchez MT, et al. Phospholipids in lipoproteins: compositional differences across VLDL, LDL, and HDL in pregnant women. Lipids Health Dis. 2019;18:20.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Neill AM, Hackett GA, Overton C, Byrne CD. Active management of acute hyperlipidaemic pancreatitis in pregnancy. J Obstet Gynaecol. 1998;18:174–5.

    Article  CAS  Google Scholar 

  16. Dzenkeviciute V, Skujaite A, Rinkuniene E, Petrulioniene Z, Gumbiene L et al. Pregnancy-related severe hypertriglyceridemia. J Clin Lipidology 2015;10:4, 299–304.

    Article  CAS  Google Scholar 

  17. Adiamah A, Psaltis E, Crook M, Lobo DN. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clin Nutr. 2017;37(6 Pt A):1810–22.

    PubMed  Google Scholar 

  18. Cahalane AM, Smith MJ, Ryan J, Maguire D. Acute pancreatitis secondary to gestational hypertriglyceridaemia. Case Rep Med. 2012;2012:627890.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Procopciuc LM, Hazi GM, Caracostea G, Nemeti G, Olteanu I, Stamatian F. Apolipoprotein E polymorphism - a risk factor in Romanian pregnant women with preeclampsia. GINECO RO volume: 7. Issue. 2011;3:134–40.

    Google Scholar 

  20. Kadikoylu G, Yukselen V, Yavasoglu I, Coskun A, Karaoglu AO, Bolaman Z. Emergent therapy with thera- peutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia. Transfusion and Apheresis Sci- ence. 2010;43(3):285–9.

    Article  Google Scholar 

  21. Lindkvist B, Appelros S, Regnér S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology. 2012;12:317–24.

    Article  CAS  PubMed  Google Scholar 

  22. Woodhead N, Nkwam O, Caddick V, Morad S, Mylvaganam S. Surgical causes of acute abdominal pain in pregnancy. Obstet Gynaecol. 2019;21:27–35.

    Article  Google Scholar 

  23. Zachariah SK, Fenn M, Jacob K, Arthungal SA, Zachariah SA. Management of acute abdomen in pregnancy: current perspectives. Int J Women's Health. 2019;11:119–34. Published 2019 Feb 8.

    Article  Google Scholar 

  24. Sezgin O, Özdoğan O, Yaraş S, Üçbilek E, Altıntaş E. Evaluation of hypertriglyceridemia-induced acute pancreatitis: a single tertiary care unit experience from Turkey. Turk J Gastroenterol. 2019;30(3):271–7.

    Article  PubMed  Google Scholar 

  25. Briggs G, Examining the safety of lipid-lowering drugs in pregnancy. 2016, retrieved from

    Google Scholar 

  26. Barrett HL, Marloes DN, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy: is it time to target lipids? Diabetes Care. 2014;37:1484–93.

    Article  CAS  PubMed  Google Scholar 

  27. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA cholesterol guideline panel. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.

    Article  PubMed  Google Scholar 

  28. Al-Shali K, Wang J, Fellows F, et al. Successful pregnancy out- come in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. Clin Biochem. 2002;35:125–30.

    Article  Google Scholar 

  29. Tsai EC, Brown JA, Veldee MY. Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: a case report. BMC Pregnancy Childbirth. 2004;4:27.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clin J Gastroenterol. 2018;11(6):441–8.

    Article  Google Scholar 

  31. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL II, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38–81

    Article  CAS  Google Scholar 

  32. Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem. 1955;215(1):15–26.

    CAS  PubMed  Google Scholar 

  33. Watts GF, Cameron J, Henderson A, Richmond W. Lipoprotein lipase deficiency due to long-term heparinization presenting as severe hypertriglyceridaemia in pregnancy. Postgrad Med J. 1991;67(794):1062–4.

    Article  CAS  Google Scholar 

  34. Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher. 2003;18:181–5.

    Article  PubMed  Google Scholar 

  35. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149–62.

    Article  PubMed  Google Scholar 

  36. Klingel R, Go Hlen B, Schwarting A, Himmelsbach F, Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial. 2003;7:359–64.

    Article  Google Scholar 

  37. Safi F, Toumeh A, Abuissa Qadan MA, Karaz R, AlAkdar B, Assaly R. Management of familial hypertriglyceridemia-induced pancreatitis during pregnancy with therapeutic plasma exchange: a case report and review of literature. Am J Ther. 2014;21(5):e134–6.

    Article  PubMed  Google Scholar 

  38. Altun D, Eren G, Cukurova Z, Hergu ̈nsel O, Yasar L. An alternative treatment in hypertriglyceridemia-induced acute pancreatitis in pregnancy: plasmapheresis. J Anaesthesiol Clin Pharmacol. 2012;28:252–4.

    Article  Google Scholar 

  39. Huang C, Liu J, Lu Y, Fan J, Wang X, Liu J, Zhang W, Zeng Y. Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a retrospective study. J Clin Apher. 2016;31(6):571–8. Epub 2016 Mar 4.

    Article  PubMed  Google Scholar 

  40. Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10(15):2272–4.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in preg- nancy. J Clin Endocrinol Metab. 2012;97:2589–96.

    Article  CAS  Google Scholar 

  42. Yang N, Li B, Pan Y, Tu J, Liu G, et al. Hypertriglyceridaemia delays pancreatic regeneration after acute pancreatitis in mice and patients. Gut. 2019;68:378–80.

    Article  CAS  Google Scholar 

  43. Tang M, Xu JM, Song SS, Mei Q, Zhang LJ. What may cause fetus loss from acute pancreatitis in pregnancy: analysis of 54 cases. Medicine (Baltimore). 2018;97(7):e9755.

    Article  Google Scholar 

  44. Cortés-Vásquez J, Noreña I, Mockus I. Hypertriglyceridemia and adverse outcomes during pregnancy. Rev Fac Med. 2018;66(2):247–53.

    Article  Google Scholar 

  45. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100(11):2680–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Frantz E, Menezes HS, Lange KC, et al. The effect of maternal hypercholesterolemia on the placenta and fetal arteries in rabbits. Acta Cir Bras. 2012;27(1):7–12.

    Article  Google Scholar 

  47. Grimes SB, Wild R. Effect of pregnancy on lipid metabolism and lipoprotein levels: Endotext.

  48. DeRuiter MC, Alkemade FE, Gittenberger-de Groot AC, Poelmann RE, Havekes LM, van Dijk KW. Maternal transmission of risk for atherosclerosis. Curr Opin Lipidol. 2008;19(4):333–7.

    Article  CAS  PubMed  Google Scholar 

  49. Goharkhay N, Tamayo EH, Yin H, et al. Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. Am J Obstet Gynecol. 2008;199(3):273):e271–6.

    Article  Google Scholar 

  50. Palinski W, D'Armiento FP, Witztum JL, et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ Res. 2001;89(11):991–6.

    Article  CAS  Google Scholar 

  51. Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36:506–9.

    Article  Google Scholar 

  52. MacIntosh MCM, Fleming KM, Bailey JA. Perinatal mortal- ity and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: popula- tion based study. BMJ. 2006;333:177.

    Article  Google Scholar 

  53. Basar R, Uzum AK, Canbaz B, Dogansen SC, Kalayoglu-Besisik S. Therapeutic apheresis for severe hypertriglyceridemia in pregnancy. Arch Gynecol Obstet. 2013;287:839–43.

    Article  CAS  Google Scholar 

  54. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45–63.

    Article  CAS  Google Scholar 

  55. Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689–94.

    Article  CAS  Google Scholar 

  56. Hernandez A, Petrov MS, Brooks DC, Banks PA, Ashley SW, Tavakkolizadeh A. Acute pancreatitis and pregnancy: a 10-year single center experience. J Gastrointest Surg. 2007;11:1623–7.

    Article  Google Scholar 

  57. Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Koutroumpakis E, Slivka A, Furlan A, Dasyam AK, Dudekula A, et al. Management and outcomes of acute pancreatitis patients over the last decade: A US tertiary-center experience. Pancreatology. 2017;17(1):32–40. Epub 2016 Oct 24.

    Article  PubMed  Google Scholar 

  59. Ducarme G, Maire F, Chatel P, et al. Acute pancreatitis during pregnancy: a review. J Perinatol. 2014;34:87–94.

    Article  CAS  PubMed  Google Scholar 

  60. Crockett SD, et al. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. Gastroenterology. 2018;154(4):1096–101.

    Article  Google Scholar 

  61. Gayam V, Mandal AK, Garlapati P, Khalid M, Gill A, et al. Moderate Hypertriglyceridemia Causing Recurrent Pancreatitis: A Case Report and the Literature Review. Case Rep Gastrointest Med. 2018;2018:4.

    Article  Google Scholar 

Download references




No funding was received for the preparation of this study.

Author information

Authors and Affiliations



Cruciat Gheorghe was the main coordinator of the project and was responsible for the study design. Gheorghe Cruciat and Georgiana Nemeti drafted the manuscript of the present paper. Florian Andreea was involved in the supervising of data collection and stratification. Goidescu Iulian contributed to data assembly and analysis. Stefan Anitan contributed with manuscript revision. All authors contributed intellectually to this manuscript and have approved this final version.

Corresponding author

Correspondence to Georgiana Nemeti.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cruciat, G., Nemeti, G., Goidescu, I. et al. Hypertriglyceridemia triggered acute pancreatitis in pregnancy – diagnostic approach, management and follow-up care. Lipids Health Dis 19, 2 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: